Viking Therapeutics VKTX 深 沪
等待开盘 08-20 09:30:00 美东时间
35.98
+2.610
+7.82%
华盛通- 最 高36.26
- 今 开34.10
- 成交量 268.62万股
- 最 低 33.8301
- 昨 收 33.37
- 总市值 41.97亿
- 52周最高 43.15
- 市盈率 静 --
- 换手率 2.30%
- 52周最低 22.959
- 委 比 73.91%
- 总股本 1.17亿
- 历史最高 99.41
- 量 比 1.48
- 振 幅 7.28%
- 历史最低 0.88
- 每 手 1
- 风险率 3.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65
JP Morgan analyst Hardik Parikh maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target from $75 to $65.
08-11 22:50
Eli Lilly and Co Stock (LLY) Moved Up by 6.32% on Aug 5: A Full Analysis
• Eli Lilly shares rose following strong quarterly earnings and increased full-year financial guidance. • Expanding clinical applications for metabolic drugs have broadened the company’s total addressable market. • Increased manufacturing capacity has improved supply, supporting sustained demand for key pharmaceutical products.
08-05 14:15
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114
Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $107 to $114.
07-30 23:56
财报速睇 | Viking Therapeutics 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.28亿美元，同比亏损扩大95.3%
华盛资讯7月30日讯，Viking Therapeutics公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.28亿美元，同比亏损扩大95.3%。
07-30 05:51
财报速睇 | Viking Therapeutics 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.28亿美元，同比亏损扩大93.9%
华盛资讯7月30日讯，Viking Therapeutics公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.28亿美元，同比亏损扩大93.9%。
07-30 04:30
Viking Therapeutics Q2 EPS $(1.10) Beats $(1.25) Estimate
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(1.25) by 12 percent. This is a 89.66 percent decrease over losses of $(0.58) per share from the same period last year.
07-30 04:08
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX...
07-22 04:41
Here’s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years
Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 10 years by 26.85% on an annualized basis producing an average annual return of 40.15%. Currently, Viking Therapeutics has a market capitalization of $4.47 billion. Buying $1000 In VKTX: If an investor had bought $1000 of VK...
07-11 00:18
